Regulatory
FDA Approves NovaCor™ Elite for Low Surgical Risk Patients with Bicuspid Aortic Valve
March 18, 2025
Financial
CardioNova Reports Q4 and Full-Year 2024 Financial Results; Announces 12% Dividend Increase
February 12, 2025
Innovation
CardioNova and Mayo Clinic Launch Collaborative Research Program in AI-Guided Structural Heart Imaging
January 30, 2025
Latest News
Clinical Data
May 14, 2025
NOVA-TRICUSPID Trial Enrollment Complete; One-Year Follow-Up Underway for NovaTri™ Replace System
Read More →
Global Access
April 28, 2025
CardioNova Expands CardioAccess Program to 12 New Countries in Sub-Saharan Africa, Providing Structural Heart Therapies to Under-Resourced Hospitals
Read More →
Awards
April 10, 2025
CardioNova Named to Fortune's "World's Most Admired Companies" List for the 7th Consecutive Year
Read More →
Partnership
March 25, 2025
CardioNova and Heartflow Partner to Integrate CT-FFR Analysis with NovaCor™ TAVR Planning Workflow
Read More →
Sustainability
March 5, 2025
CardioNova Publishes Inaugural ESG Report; Commits to Science-Based Targets and Scope 3 Emissions Reduction
Read More →
R&D
February 20, 2025
CardioNova Receives FDA Breakthrough Device Designation for Next-Generation Transcatheter Mitral Valve Replacement System
Read More →Press Releases
CardioNova Therapeutics Reports First Quarter 2025 Financial Results
May 7, 2025
Read Full Release →CardioNova Receives FDA Approval for NovaCor™ Elite in Bicuspid Aortic Valve — Expanding TAVR Indication to New Patient Population
March 18, 2025
Read Full Release →CardioNova Announces Definitive Agreement to Acquire Cordance Medical — Adding Remote Hemodynamic Monitoring to Portfolio
February 28, 2025
Read Full Release →CardioNova Reports Full-Year 2024 Financial Results; Announces 12% Dividend Increase and $1.5B Share Repurchase Program
February 12, 2025
Read Full Release →
Media Resources
Press Kit
Download CardioNova's press kit including company overview, executive bios, product descriptions, and high-resolution images.
Download Press Kit →
Brand Assets
Official CardioNova logos, brand guidelines, and product imagery for media use. All assets are available in multiple formats.
Access Brand Assets →
Fact Sheet
A concise overview of CardioNova Therapeutics — our mission, size, key products, and financial highlights — in a single-page format.
Download Fact Sheet →